Infant immunization with pneumococcal CRM197 vaccines

Effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines

Robert S. Daum, Deborah Hogerman, Margaret B. Rennels, Kathleen Bewley, Frank Malinoski, Edward Rothstein, Keith Reisinger, Stan Block, Harry Keyserling, Mark Steinhoff

Research output: Contribution to journalArticle

Abstract

Six pentavalent pneumococcal conjugate vaccines (Pn-CRM197) were evaluated among 400 infants. The vaccines differed in saccharide chain length (oligosaccharide [OS] or polysaccharide [PS]) and saccharide quantity (0.5, 2, or 5 μg). Subjects were randomized into groups 1-6 (Pn-CRM197 recipients) or 7 (controls) for immunization at 2, 4, and 6 months of age. Pn-CRM197 were well tolerated and elicited mean antibody concentrations that exceeded those in controls for all 5 capsular serotypes. PS formulations were generally more immunogenic than their OS counterparts. For PS vaccines, a dose-response was documented (5 μg > 2 μg > 0.5 μg), but the differences between the 5- and 2-μg formulations were insignificant. The mean anti-PRP antibody concentration was significantly higher among Pn-CRM197 recipients. It is concluded that PS vaccines are more immunogenic than OS vaccines. The improved immunogenicity from Haemophilus type b oligosaccharide conjugate (HbOC) vaccine when given with Pn-CRM197 suggests that a decreased dose of HbOC vaccine may be sufficient to elicit protection.

Original languageEnglish (US)
Pages (from-to)445-455
Number of pages11
JournalJournal of Infectious Diseases
Volume176
Issue number2
StatePublished - 1997
Externally publishedYes

Fingerprint

Pneumococcal Vaccines
Oligosaccharides
Immunization
Vaccines
Conjugate Vaccines
Polysaccharides
Haemophilus
Anti-Idiotypic Antibodies
CRM197 (non-toxic variant of diphtheria toxin)
Antibodies

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Daum, R. S., Hogerman, D., Rennels, M. B., Bewley, K., Malinoski, F., Rothstein, E., ... Steinhoff, M. (1997). Infant immunization with pneumococcal CRM197 vaccines: Effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines. Journal of Infectious Diseases, 176(2), 445-455.

Infant immunization with pneumococcal CRM197 vaccines : Effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines. / Daum, Robert S.; Hogerman, Deborah; Rennels, Margaret B.; Bewley, Kathleen; Malinoski, Frank; Rothstein, Edward; Reisinger, Keith; Block, Stan; Keyserling, Harry; Steinhoff, Mark.

In: Journal of Infectious Diseases, Vol. 176, No. 2, 1997, p. 445-455.

Research output: Contribution to journalArticle

Daum, RS, Hogerman, D, Rennels, MB, Bewley, K, Malinoski, F, Rothstein, E, Reisinger, K, Block, S, Keyserling, H & Steinhoff, M 1997, 'Infant immunization with pneumococcal CRM197 vaccines: Effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines', Journal of Infectious Diseases, vol. 176, no. 2, pp. 445-455.
Daum, Robert S. ; Hogerman, Deborah ; Rennels, Margaret B. ; Bewley, Kathleen ; Malinoski, Frank ; Rothstein, Edward ; Reisinger, Keith ; Block, Stan ; Keyserling, Harry ; Steinhoff, Mark. / Infant immunization with pneumococcal CRM197 vaccines : Effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines. In: Journal of Infectious Diseases. 1997 ; Vol. 176, No. 2. pp. 445-455.
@article{ac416d2ef38e4da9bb9d38fe62006058,
title = "Infant immunization with pneumococcal CRM197 vaccines: Effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines",
abstract = "Six pentavalent pneumococcal conjugate vaccines (Pn-CRM197) were evaluated among 400 infants. The vaccines differed in saccharide chain length (oligosaccharide [OS] or polysaccharide [PS]) and saccharide quantity (0.5, 2, or 5 μg). Subjects were randomized into groups 1-6 (Pn-CRM197 recipients) or 7 (controls) for immunization at 2, 4, and 6 months of age. Pn-CRM197 were well tolerated and elicited mean antibody concentrations that exceeded those in controls for all 5 capsular serotypes. PS formulations were generally more immunogenic than their OS counterparts. For PS vaccines, a dose-response was documented (5 μg > 2 μg > 0.5 μg), but the differences between the 5- and 2-μg formulations were insignificant. The mean anti-PRP antibody concentration was significantly higher among Pn-CRM197 recipients. It is concluded that PS vaccines are more immunogenic than OS vaccines. The improved immunogenicity from Haemophilus type b oligosaccharide conjugate (HbOC) vaccine when given with Pn-CRM197 suggests that a decreased dose of HbOC vaccine may be sufficient to elicit protection.",
author = "Daum, {Robert S.} and Deborah Hogerman and Rennels, {Margaret B.} and Kathleen Bewley and Frank Malinoski and Edward Rothstein and Keith Reisinger and Stan Block and Harry Keyserling and Mark Steinhoff",
year = "1997",
language = "English (US)",
volume = "176",
pages = "445--455",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Infant immunization with pneumococcal CRM197 vaccines

T2 - Effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines

AU - Daum, Robert S.

AU - Hogerman, Deborah

AU - Rennels, Margaret B.

AU - Bewley, Kathleen

AU - Malinoski, Frank

AU - Rothstein, Edward

AU - Reisinger, Keith

AU - Block, Stan

AU - Keyserling, Harry

AU - Steinhoff, Mark

PY - 1997

Y1 - 1997

N2 - Six pentavalent pneumococcal conjugate vaccines (Pn-CRM197) were evaluated among 400 infants. The vaccines differed in saccharide chain length (oligosaccharide [OS] or polysaccharide [PS]) and saccharide quantity (0.5, 2, or 5 μg). Subjects were randomized into groups 1-6 (Pn-CRM197 recipients) or 7 (controls) for immunization at 2, 4, and 6 months of age. Pn-CRM197 were well tolerated and elicited mean antibody concentrations that exceeded those in controls for all 5 capsular serotypes. PS formulations were generally more immunogenic than their OS counterparts. For PS vaccines, a dose-response was documented (5 μg > 2 μg > 0.5 μg), but the differences between the 5- and 2-μg formulations were insignificant. The mean anti-PRP antibody concentration was significantly higher among Pn-CRM197 recipients. It is concluded that PS vaccines are more immunogenic than OS vaccines. The improved immunogenicity from Haemophilus type b oligosaccharide conjugate (HbOC) vaccine when given with Pn-CRM197 suggests that a decreased dose of HbOC vaccine may be sufficient to elicit protection.

AB - Six pentavalent pneumococcal conjugate vaccines (Pn-CRM197) were evaluated among 400 infants. The vaccines differed in saccharide chain length (oligosaccharide [OS] or polysaccharide [PS]) and saccharide quantity (0.5, 2, or 5 μg). Subjects were randomized into groups 1-6 (Pn-CRM197 recipients) or 7 (controls) for immunization at 2, 4, and 6 months of age. Pn-CRM197 were well tolerated and elicited mean antibody concentrations that exceeded those in controls for all 5 capsular serotypes. PS formulations were generally more immunogenic than their OS counterparts. For PS vaccines, a dose-response was documented (5 μg > 2 μg > 0.5 μg), but the differences between the 5- and 2-μg formulations were insignificant. The mean anti-PRP antibody concentration was significantly higher among Pn-CRM197 recipients. It is concluded that PS vaccines are more immunogenic than OS vaccines. The improved immunogenicity from Haemophilus type b oligosaccharide conjugate (HbOC) vaccine when given with Pn-CRM197 suggests that a decreased dose of HbOC vaccine may be sufficient to elicit protection.

UR - http://www.scopus.com/inward/record.url?scp=16944366702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16944366702&partnerID=8YFLogxK

M3 - Article

VL - 176

SP - 445

EP - 455

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 2

ER -